Skip to main content
logo
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.86
+7.27 (7.53%)
At close: Nov 6, 2026, 4:00 PM EST
103.00
-0.86 (-0.83%)
After-hours: Nov 6, 2026, 7:30 PM EST

Spyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-263.86-155.2-208.02-338.79-83.82-65.8
Depreciation & Amortization
---0.961.962
Loss (Gain) From Sale of Assets
-70-10--15.53--
Asset Writedown & Restructuring Costs
---132.77--
Loss (Gain) From Sale of Investments
-11.58-8.09-11.4-2.32-0.330.55
Stock-Based Compensation
50.337.6144.8325.687.118.04
Other Operating Activities
48.3-27.6421.71102.530.43-0.34
Change in Accounts Receivable
---0.380.44-0.82
Change in Accounts Payable
-1.887.65-16.21-2.18-2.641.07
Change in Unearned Revenue
---0.58-0.883.58
Change in Other Net Operating Assets
-0.61-13.5811.68-3.97-2.42-1.99
Operating Cash Flow
-249.32-169.25-157.41-99.91-80.14-53.72
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-----0.04-0.57
Sale of Property, Plant & Equipment
---0.48--
Cash Acquisitions
---3.04--
Sale (Purchase) of Intangibles
707-15--
Investment in Securities
-562.54-150.48-353.29-126.957.05-22.05
Investing Cash Flow
-492.54-143.48-353.29-108.3957.01-22.62

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
-----0.42-0.51
Net Debt Issued (Repaid)
-----0.42-0.51
Issuance of Common Stock
816.24314.44243.8984.9643.11.9
Other Financing Activities
-56.56-5.41-1.84-5.8--
Financing Cash Flow
759.69309.03410.91361.0842.681.39

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
---00.03-0.11-0.02
Net Cash Flow
17.83-3.7-99.79152.819.44-74.96

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-249.32-169.25-157.41-99.91-80.18-54.29
Free Cash Flow Growth
------
Free Cash Flow Margin
----11276.52%-3442.76%-289.71%
Free Cash Flow Per Share
-3.04-2.64-3.35-14.49-23.78-20.64
Levered Free Cash Flow
-95.36-103.85-66.57-9.61-50.01-30.62
Unlevered Free Cash Flow
-95.36-103.85-66.57-9.61-50.01-30.62

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-2.49-5.93-4.53-5.21-5.51.83
SEC Filings: 10-K · 10-Q